MeMed Key
A cuttig edge, compact immunoassay platform.
불필요한 항생제 처방의 시대는 끝났습니다. 이제, 데이터로 결정하십시오.
Host Response 기반의 혁신적인 기술로 15분 만에 감염의 원인(Viral vs Bacterial Infection)의 원인을 정확히 구분합니다.
진단의 불확실성을 계량화한 항생제 처방의 새로운 기준, MeMed BV®
MeMed BV® – Rapidly diagnose infection etiology Powered by Host Response
Is it bacterial or viral?
Now you know in 15 minutes!
Clinically Proven Accuracy in Bacterial vs. Viral Differentiation
Bacterial and viral infections often present with similar symptoms, making treatment decisions difficult.
MeMed BV® uses host response data to quickly and accurately differentiate between them—empowering physicians to make faster, more informed choices and reduce unnecessary antibiotic use.
Antibiotic Misuse Is Often a Result of Diagnostic Uncertainty
antibiotic overuse 1
antibiotic underuse2
단순한 수치를 넘어 알고리즘으로 진단합니다 : Three Biomarkers + Machine Learning
소량의 혈액만으로 세균성인지 바이러스성인지 즉각적인 결론을 제공합니다. FDA 승인 기술로 검증된 정확함을 진료실에서 확인하십시오
Three Biomarkers + Machine Learning = MeMed BV
15 Minutes. 3 Biomarkers. 1 Score.
From a small serum or venous whole blood sample,* the FDA-cleared MeMed BV® delivers actionable results in 15 minutes. No guessing. No waiting. Just clarity when treatment decisions can’t wait.
Advanced Science. Simple Answers.
MeMed BV® turns complex immune signals into one clear result. Powered by machine learning and three host-response biomarkers—TRAIL, IP-10, and CRP—it tells you: bacterial or viral. Fast.
Clarity from Host Response
Behind MeMed BV® is a powerful algorithm that turns host protein levels into one easy-to-read score—helping clinicians act fast, with confidence and precision.
97% AUC, 숫자가 증명하는 감염 진단의 정확도
전 세계 20,000명 이상의 환자를 대상으로 한 대규모 다국가 임상(Apollo Study 등)을 통해 입증되었습니다.
AUC
MeMed BV Performance
MeMed BV® performance has been independently confirmed through blinded validation and real-world evidence across more than 20,000 patients. The FDA clinical study (Apollo) was conducted to establish the diagnostic performance of the MeMed BV® test for differentiating bacterial from viral infection in patients with suspected acute bacterial or viral infection.3
Consisten Accuracy Across Settings ans Populations.
Our unique emphasis on quality and breadth of clinical evidence sets MeMed apart. MeMed BV performance has been validated in multi-national, double-blind clinical studies and real world settings enrolling almost 20,000 subjects in Europe, Israel and the United States.3-13 These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes.
CONTACT NOW
Are you interested in the product?
We’d love to hear from you. Get in touch with us just below to request an offer!